
 
 
 
 
 
 
 
 
  What is claimed is:  
   
 1.    A method of treating a Trop-2 expressing cancer comprising administering to a subject with a Trop-2 expressing cancer an antibody-drug conjugate (ADC) comprising (i) an anti-Trop-2 antibody or antigen-binding fragment thereof; and (ii) a cytotoxic drug conjugated to the anti-Trop-2 antibody or antibody fragment.  
 
     
 2.    The method of claim 1, wherein the anti-Trop-2 antibody is a chimeric, humanized or human antibody.  
 
     
 3.    The method of claim 1, wherein the anti-Trop-2 antibody is selected from the group consisting of hRS7, 162-46.2, MAB650, K5-70, K5-107, K5-116-2-1, T6-16, T5-86, BR110, 3E9, 6G11, 7E6, 15E2, 18B1, 77220, KM4097, KM4590, A1, A3, and 162-25.3; or wherein the antibody is produced by a hybridoma selected from the group consisting of AR47A6.4.2, AR52A301.5, PTA-12871, PTA-12872, PD 08019, PD  08020, and PD 08021.  
 
     
 4.    The method of claim 1, wherein the anti-Trop-2 antibody is selected from the group consisting of hRS7, 162-46.2 and MAB650.  
 
     
 5.    The method of claim 1, wherein the antibody is an IgG1, IgG2, IgG3 or IgG4 antibody.  
 
     
 6.    The method of claim 1, wherein the antibody allotype is selected from the group consisting of nG1m1, G1m3, G1m3,1, G13,2, G1m3,1,2, and Km3.  
 
     
 7.    The method of claim 1, wherein the drug is selected from the group consisting of an anthracycline, a camptothecin, a tubulin inhibitor, a maytansinoid, a calicheamycin, an auristatin, a nitrogen mustard, an ethylenimine derivative, an alkyl sulfonate, a nitrosourea, a triazene, a folic acid analog, a taxane, a COX-2 inhibitor, a pyrimidine analog, a purine analog, an antibiotic, an enzyme inhibitor, an epipodophyllotoxin, a platinum coordination complex, a vinca alkaloid, a substituted urea, a methyl hydrazine derivative, an adrenocortical suppressant, a hormone antagonist, an antimetabolite, an alkylating agent, an antimitotic, an anti-angiogenic agent, a tyrosine kinase inhibitor, an mTOR inhibitor, a heat shock protein (HSP90) inhibitor, a proteosome inhibitor, an HDAC inhibitor, and a pro-apoptotic agent.  
 
     
 8.    The method of claim 1, wherein the drug is selected from the group consisting of 5-fluorouracil, afatinib, aplidin, azaribine, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatinum, COX-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, DM1, DM3, DM4, doxorubicin, 2-pyrrolinodoxorubicine (2-PDox), a pro-drug form of 2-PDox (pro-2-PDox), cyano-morpholino doxorubicin, doxorubicin glucuronide, endostatin, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, monomethylauristatin F  (MMAF), monomethylauristatin D (MMAD), monomethylauristatin E (MMAE), navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, SN-38, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids and ZD1839.  
 
     
 9.        The method of claim 1, wherein the drug is selected from the group consisting of SN-38, pro-2-pyrrolinodoxorubicin (pro-2-PDox), paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD and MMAF.  
 
     
 10. The method of claim 1, wherein the average ratio of drug to antibody is between 1 and 12.  
 
     
 11. The method of claim 1, wherein the average ratio of drug to antibody is between 1.5 and 8.  
 
     
 12. The method of claim 1, wherein the average ratio of drug to antibody is between 1 and 6.  
 
     
 13. The method of claim 1, wherein the average ratio of drug to antibody is less than 6.  
 
     
 14. The method of claim 1, wherein the average ratio of drug to antibody is about 6.  
 
     
 15. The method of claim 1, wherein the cancer is selected from the group consisting of breast, ovarian, cervical, endometrial, lung, prostate, colorectal, stomach, esophageal, bladder, renal, pancreatic, thyroid, and head-and-neck cancers.  
 
     
 16. The method of claim 1, wherein the cancer is resistant to treatment with at least one anti-cancer therapy.  
 
     
 17. The method of claim 1, wherein the cancer is resistant to treatment with a topoisomerase 1 or topoisomerase 2 inhibitor.  
 
     
 18. The method of claim 17, wherein the cancer is resistant to treatment with irinotecan or SN-38.  
 
     
 19. The method of claim 16, wherein the cancer is selected from the group consisting of pancreatic cancer, triple-negative breast cancer, metastatic colorectal cancer, a HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer (NSCLC), metastatic pancreatic cancer, metastatic renal cell carcinoma, metastatic gastric cancer, metastatic prostate cancer, metastataic esophageal cancer, metastatic urinary bladder cancer, and metastatic small-cell lung cancer.  
 
     
 20. The method of claim 1, further comprising treating the subject with one or more therapies selected from the group consisting of surgery, radiation therapy, chemotherapy, an immunomodulator, a cytokine, a chemotherapeutic agent, a pro-apoptotic agent, an anti-angiogenic agent, a cytotoxic agent, a drug, a toxin, a radionuclide, an RNAi, an siRNA, a second antibody, an antigen-binding fragment of a second antibody, an RNase, a DNase, and an immunoconjugate.  
 
     
 21. The method of claim 20, wherein the therapy comprises administration of an anti-Trop-2 agent selected from the group consisting of VB4-845, IGN-101, adecatumumab, and EMD 273 066.  
 
     
 22. The method of claim 20, wherein the therapy comprises administration of an anti-MUC5ac antibody or antigen-binding antibody fragment.  
 
     
 23. The method of claim 20, wherein the therapy comprises administration of 90Y-hPAM4.  
 
     
 24. The method of claim 23, wherein the cancer is pancreatic cancer.  
 
     
 25. The method of claim 20, wherein the drug is selected from the group consisting of 5-fluorouracil, afatinib, aplidin, azaribine, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatinum, COX-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, DM1, DM3, DM4, doxorubicin, 2-pyrrolinodoxorubicine (2-PDox), a pro-drug form of 2-PDox (pro-2-PDox), cyano-morpholino doxorubicin, doxorubicin glucuronide, endostatin, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, monomethylauristatin F  (MMAF), monomethylauristatin D (MMAD), monomethylauristatin E (MMAE), navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-34I, raloxifene, semustine, SN-38, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids and ZD1 839.  
 
     
 26. The method of claim 20, wherein the radionuclide is selected from the group consisting of 11C, 13N, 15O, 32P, 33P, 47Sc, 51Cr, 57Co, 58Co, 59Fe, 62Cu, 67Cu, 67Ga, 67Ga, 75Br, 75Se, 75Se, 76Br, 77As, 77Br, 80m Br, 89Sr, 90Y, 95Ru, 97Ru, 99Mo, 99m Tc, 103m Rh, 103Ru, 105Rh, 105Ru, 107Hg, 109Pd, 109Pt, 111Ag, 111In , 113In, 119Sb, 121m Te, 122m Te, 125I, 125m Te, 126I, 131I, 133I, 142Pr, 143Pr, 149Pm, 152Dy, 153Sm, 161Ho, 161Tb, 165Tm, 166Dy, 166Ho, 167Tm, 168Tm, 169Er, 169Yb, 177Lu, 186Re, 188Re, 189Os, 189Re, 192Ir, 194Ir, 197Pt, 198Au, 199Au, 199Au, 201TI, 103Hg, 211At, 211Bi, 211Pb, 212Bi, 212Pb, 213Bi, 215Po, 217At, 219Rn, 221Fr, 223Ra, 224Ac, 225Ac, 255Fm and 227Th.  
 
     
 27. The method of claim 20, wherein the toxin is selected from the group consisting of ricin, abrin, alpha toxin, saporin, ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.  
 
     
 28. The method of claim 20, wherein the immunomodulator is selected from the group consisting of a cytokine, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor (CSF), an interferon (IFN), an interleukin, erythropoietin and thrombopoietin.  
 
     
 29. The method of claim 20, wherein the cytokine is selected from the group consisting of human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, tumor necrosis factor-.alpha., tumor necrosis factor-.beta., mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), NGF-.beta., platelet-growth factor, TGF-.alpha., TGF-.beta., insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, interferon-.alpha., interferon-.beta., interferon-.gamma., macrophage-CSF  (M-CSF), IL-1, IL-1.alpha., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, LIF, FLT-3, angiostatin, thrombospondin, endostatin, tumor necrosis factor and lymphotoxin.  
 
     
 30. The method of claim 20, wherein the second antibody, second antibody fragment or immunoconjugate binds to an antigen selected from the group consisting of carbonic anhydrase IX, B7, CCL19, CCL21, CSAp, HER-2/neu, BrE3, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD59, CD64, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5, CEACAM6, CTLA-4, alpha-fetoprotein (AFP), VEGF, ED-B fibronectin, EGP-1 (Trop-2), EGP-2, EGF receptor, ErbB2, ErbB3, Factor H, Flt-1, Flt-3, folate receptor, Ga 733,GRO-.beta., HMGB-1, hypoxia inducible factor, HM1.24, HER-2/neu, histone H2B, histone H3, histone H4, insulin-like growth factor, IFN-.gamma., IFN-.alpha., IFN-.beta., IFN-.lambda., IL-2R, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-2, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, IGF-1R, Ia, HM1.24, gangliosides, HCG, HLA-DR, CD66a-d, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, macrophage migration-inhibitory factor (MIF), matrix metalloproteinase-2, matrix metalloproteinase-9, matrix metalloproteinase-12, MUC1, MUC2, MUC3, MUC4, MUC5ac, placental growth factor, PSA (prostate-specific antigen), PSMA, PD-1 receptor, PD-L1, NCA-95, NCA-90, A3, A33, Ep-CAM, KS-1, Le(y), mesothelin, S100, tenascin, TAC, Tn antigen, Thomas-Friedenreich antigens, tumor necrosis antigens, tumor angiogenesis antigens, TNF-.alpha., TRAIL  receptor R1, TRAIL receptor R2, VEGFR, RANTES, T101, complement factors C3, C3a, C3b, C5a, C5, and an oncogene product.  
 
     
 31. The method of claim 1, wherein the antibody fragment is selected from the group consisting of F(aN)2, Fab', Fab, Fv, scFv, single-domain antibody and IgG4 half-molecule.  
 
     
 32. The method of claim 1, wherein the anti-Trop-2 antibody or fragment thereof comprises the light chain CDR sequences CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID  NO:6).  
 
     
 33. The method of claim 1, wherein the anti-Trop-2 antibody or fragment thereof binds to the same epitope as an anti-Trop-2 antibody comprising the light chain CDR  sequences CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6).  
 
     
 34. The method of claim 1, wherein the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells and wherein adminstration of the anti-Trop-2 ADC to the subject does not induce a fatal immune response to the ADC.  
 
     
 35. The method of claim 34, wherein administration of the anti-Trop-2 ADC to the subject at a therapeutically effective dosage results in limited toxicity.  
 
     
 36. The method of claim 35, wherein administration of the anti-Trop-2 ADC to the subject results in <= Grade 3 neutropenia, nausea, diarrhea, alopecia or vomiting.  
 
     
 37. A method of killing a Trop-2 expressing cell comprising exposing the cell to an antibody-drug conjugate (ADC) comprising (i) an anti-Trop-2 antibody or antigen-binding fragment thereof; and (ii) a cytotoxic drug conjugated to the anti-Trop-2 antibody or antibody fragment.  
 
     
 38. A method of delivering a cytotoxic drug to a Trop-2 expressing cell comprising exposing the cell to an antibody-drug conjugate (ADC) comprising (i) an anti-Trop-2 antibody or antigen-binding fragment thereof; and (ii) a cytotoxic drug conjugated to the anti-Trop-2 antibody or antibody fragment.  
 
     
 39. A composition comprising an antibody-drug conjugate (ADC) comprising (i) an anti-Trop-2 antibody or antigen-binding fragment thereof; and (ii) a cytotoxic drug conjugated to the anti-Trop-2 antibody or antibody fragment.  
 
     
 40. The composition of claim 39, wherein the anti-Trop-2 antibody is a chimeric, humanized or human antibody.  
 
     
 41. The composition of claim 39, wherein the anti-Trop-2 antibody is selected from the group consisting of hRS7, 162-46.2, MAB650, K5-70, K5-107, K5-116-2-1, T6-16, 86, BR110, 3E9, 6G11, 7E6, 15E2, 18B1, 77220, KM4097, KM4590, A1, A3, and 162-25.3; or wherein the antibody is produced by a hybridoma selected from the group consisting of AR47A6.4.2, AR52A301.5, PTA-12871, PTA-12872, PD 08019, PD  08020, and PD 08021.  
 
     
 42. The composition of claim 39, wherein the anti-Trop-2 antibody is selected from the group consisting of hRS7, 162-46.2 and MAB650.  
 
     
 43. The composition of claim 39, wherein the antibody is an IgG1, IgG2, IgG3 or IgG4 antibody.  
 
     
 44. The composition of claim 39, wherein the antibody allotype is selected from the group consisting of nG1m1, G1m3, G1m3,1, G13,2, G1m3,1,2, and Km3.  
 
     
 45. The composition of claim 39, wherein the drug is selected from the group consisting of an anthracycline, a camptothecin, a tubulin inhibitor, a maytansinoid, a calicheamycin, an auristatin, a nitrogen mustard, an ethylenimine derivative, an alkyl sulfonate, a nitrosourea, a triazene, a folic acid analog, a taxane, a COX-2 inhibitor, a pyrimidine analog, a purine analog, an antibiotic, an enzyme inhibitor, an epipodophyllotoxin, a platinum coordination complex, a vinca alkaloid, a substituted urea, a methyl hydrazine derivative, an adrenocortical suppressant, a hormone antagonist, an antimetabolite, an alkylating agent, an antimitotic, an anti-angiogenic agent, a tyrosine kinase inhibitor, an mTOR inhibitor, a heat shock protein (HSP90) inhibitor, a proteosome inhibitor, an HDAC inhibitor, and a pro-apoptotic agent.  
 
     
 46. The composition of claim 39, wherein the drug is selected from the group consisting of 5-fluorouracil, afatinib, aplidin, azaribine, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatinum, COX-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, DM1, DM3, DM4, doxorubicin, 2-pyrrolinodoxorubicine (2-PDox), a pro-drug form of 2-PDox (pro-2-PDox), cyano-morpholino doxorubicin, doxorubicin glucuronide, endostatin, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, monomethylauristatin F  (MMAF), monomethylauristatin D (MMAD), monomethylauristatin E (MMAE), navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, SN-38, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids and ZD1839.  
 
     
 47. The composition of claim 39, wherein the drug is selected from the group consisting of SN-38, pro-2-pyrrolinodoxorubicin (pro-2-PDox), paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD and MMAF.  
 
     
 48. The composition of claim 39, wherein the average ratio of drug to antibody is between 1 and 12.  
 
     
 49. The composition of claim 39, wherein the average ratio of drug to antibody is between 1.5 and 8.  
 
     
 50. The composition of claim 39, wherein the average ratio of drug to antibody is between 1 and 6.  
 
     
 51. The composition of claim 39, wherein the average ratio of drug to antibody is less than 6.  
 
     
 52. The composition of claim 39, wherein the average ratio of drug to antibody is about 6.  
 
     
 53. The composition of claim 39, wherein the antibody fragment is selected from the group consisting of F(aN)2, Fab', Fab, Fv, scFv, single-domain antibody and IgG4 half-molecule.  
 
     
 54. The composition of claim 39, wherein the anti-Trop-2 antibody or fragment thereof comprises the light chain CDR sequences CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID  NO:6).  
 
     
 55. The composition of claim 39, wherein the anti-Trop-2 antibody or fragment thereof binds to the same epitope as an anti-Trop-2 antibody comprising the light chain CDR  sequences CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6).  
 
     
 56. The composition of claim 39, further comprising a therapeutic agent selected from the group consisting of an immunomodulator, a cytokine, a chemotherapeutic agent, a pro-apoptotic agent, an anti-angiogenic agent, a cytotoxic agent, a drug, a toxin, a radionuclide, an RNAi, an siRNA, a second antibody, an antigen-binding fragment of a second antibody, an RNase, a DNase, and an immunoconjugate.  
 
   
 
 
 
 
 
 
 
 
